KYUNG NAM PHARM.CO.,LTD. Logo

KYUNG NAM PHARM.CO.,LTD.

Pharmaceutical firm specializing in OTC medicines and health functional foods since 1957.

053950 | KO

Overview

Corporate Details

ISIN(s):
KR7053950002
LEI:
Country:
South Korea
Address:
경상남도 의령군 동동리 1539-5, 의령군

Description

Kyung Nam Pharm is a pharmaceutical company established in 1957 that specializes in over-the-counter (OTC) medicines and health functional foods. The company is widely known for its flagship brand, Lemona, which was the first powdered Vitamin C product in its domestic market and is now marketed as an inner-beauty product. The core product portfolio also includes PM, a topical treatment for athlete's foot, and Minol F Troche for sore throats. A key area of specialization is human placenta-based medicines; the company was a pioneer in developing and commercializing human placenta drink formulations. Kyung Nam Pharm focuses on developing accessible healthcare solutions based on its corporate philosophy of promoting human health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-10 00:00
감사보고서제출
Korean 26.3 KB
2025-03-05 00:00
주주총회소집결의
Korean 7.4 KB
2025-03-05 00:00
주주총회소집공고
Korean 187.0 KB
2025-02-21 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.8 KB
2025-02-14 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 17.9 KB
2025-02-10 00:00
전환가액의조정
Korean 19.9 KB
2025-01-22 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 12.3 KB
2025-01-10 00:00
전환가액의조정
Korean 19.5 KB
2025-01-10 00:00
주식등의대량보유상황보고서(약식)
Korean 66.5 KB
2024-12-13 00:00
주식등의대량보유상황보고서(일반)
Korean 87.8 KB
2024-12-13 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2024-12-10 00:00
전환가액의조정
Korean 19.1 KB
2024-12-03 00:00
가족친화인증ㆍ유효기간연장ㆍ인증취소(자율공시)
Korean 6.3 KB
2024-11-22 00:00
전환가액의조정
Korean 14.0 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 1.4 MB

Automate Your Workflow. Get a real-time feed of all KYUNG NAM PHARM.CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KYUNG NAM PHARM.CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KYUNG NAM PHARM.CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.